EMAIL THIS PAGE TO A FRIEND

Drug delivery and translational research

Design, synthesis and characterisation of mannosylated ovalbumin lipid core peptide self-adjuvanting vaccine delivery system.


PMID 25786879

Abstract

Peptide-based vaccine delivery can be hampered by rapid peptidase activity and poor inherent immunogenicity. The self-adjuvanting lipid core peptide system (LCP) has been shown to confer improved stability and immunogenicity on peptide epitopes of group A Streptococcus, Chlamydia, hookworm, and malaria pathogens. However, various diseases, including cancer, still require targeted delivery of their vaccine candidates. For this reason, we have selected two model peptides (ovalbumin CD4(+) and/or CD8(+) T cell epitopes), and incorporated two or four copies of either epitope into our LCP vaccine. Optimised glycosylation of ovalbumin peptides yielded 46 % when microwave-assisted double coupling with 2 eq of carbohydrate derivative, activated by N,N-diisopropylethylamine and (O-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, was performed. All ovalbumin peptides were successfully synthesised and purified in 11-55 % yields by Fmoc- or Boc-chemistry using solid-phase peptide synthesis. The mannosylated ovalbumin peptides were nontoxic to human erythrocytes in haemolytic assay (<2 % haemolysis) and showed increased (up to 20-fold) stability in plasma.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

379115
DCC, 1.0 M in methylene chloride
C13H22N2
D80002
DCC, 99%
C13H22N2
361941
Di-tert-butyl dicarbonate, ReagentPlus®, ≥99%
C10H18O5
205249
Di-tert-butyl dicarbonate, ReagentPlus®, 99%
C10H18O5
436267
Di-tert-butyl dicarbonate solution, 1.0 M in THF
C10H18O5
703753
Di-tert-butyl dicarbonate solution, 2 M in THF
C10H18O5
703737
Di-tert-butyl dicarbonate solution, 2 M in methylene chloride
C10H18O5
703745
Di-tert-butyl dicarbonate solution, 2 M in ethyl acetate
C10H18O5
D125407
DIC, 99%
C7H14N2
633267
Dicyclohexylcarbodiimide solution, 60 wt. % in xylenes
C13H22N2
901609
Diisopropylcarbodiimide solution, 1 M in dichloromethane
901594
Diisopropylcarbodiimide solution, 1 M in THF
156914
Dimethyl sulfoxide-d6, "100%", 99.96 atom % D
C2D6OS
453323
Dimethyl sulfoxide-d6, "100%", 99.96 atom % D
C2D6OS
424005
Dimethyl sulfoxide-d6, "100%", 99.96 atom % D
C2D6OS
417939
Dimethyl sulfoxide-d6, "100%", 99.96 atom % D, contains 0.03 % (v/v) TMS
C2D6OS
417920
Dimethyl sulfoxide-d6, "100%", 99.96 atom % D, contains 1 % (v/v) TMS
C2D6OS
570672
Dimethyl sulfoxide-d6, anhydrous, 99.9 atom % D
C2D6OS
151874
Dimethyl sulfoxide-d6, 99.9 atom % D
C2D6OS
522058
Dimethyl sulfoxide-d6, 99.9 atom % D
C2D6OS
716731
Dimethyl sulfoxide-d6, "Special HOH", ≥99.9 atom % D
C2D6OS
296147
Dimethyl sulfoxide-d6, 99.9 atom % D, contains 0.03 % (v/v) TMS
C2D6OS
574341
Dimethyl sulfoxide-d6, 99.9 atom % D, contains 0.03 % (v/v) TMS
C2D6OS
185965
Dimethyl sulfoxide-d6, 99.9 atom % D, contains 1 % (v/v) TMS
C2D6OS
175943
Dimethyl sulfoxide-d6, 99.5 atom % D
C2D6OS
445460
HATU, 97%
C10H15F6N6OP
496219
N,N-Diisopropylethylamine, 99.5%, biotech. grade
C8H19N
D125806
N,N-Diisopropylethylamine, ReagentPlus®, ≥99%
C8H19N
43116
N-(Diphenylmethyl)methylamine, ≥98.0% (GC)
C14H15N